**Question:** All are good prognostic factors for neuroblastoma except -

A. Metastasis
B. Age
C. Serum lactate dehydrogenase (LDH) levels
D. Serum neuron-specific enolase (NSE) levels

**Core Concept:** Neuroblastoma is a malignant tumor originating from neural crest cells, typically found in children. Prognostic factors play a crucial role in determining the disease course and treatment options. Good prognostic factors help predict a more favorable outcome, while poor prognostic factors indicate a worse prognosis.

**Why the Correct Answer is Right:**

Metastasis (option A) is a poor prognostic factor, as it indicates cancer cells have spread to other parts of the body. Age (option B) is a confusing factor, as both very young age (under 12 months) and very old age (over 10 years) are unfavorable prognostic factors due to specific challenges in treatment and higher mortality rates.

**Why Each Wrong Option is Incorrect:**

- Serum lactate dehydrogenase (option C) is a marker of tissue damage, not a direct indicator of tumor burden or response to treatment. Although lower LDH levels are generally favorable, it is not considered a strong independent prognostic factor compared to other factors like MYCN amplification or bone marrow involvement.
- Serum neuron-specific enolase (option D) is a tumor-derived protein that increases in the presence of neuroblastoma. Higher serum NSE levels indicate a higher tumor burden, poor prognosis, and a worse response to treatment.

**Why the Correct Answer is Right:**

Neuron-specific enolase (option D) is a direct marker of tumor burden and response to therapy. Low serum NSE levels are associated with better prognosis and favorable outcomes, making it a good prognostic factor.

**Clinical Pearl:**

When evaluating patients with neuroblastoma, it is essential to consider multiple factors, including age, tumor stage, MYCN gene amplification, bone marrow involvement, and biochemical markers like LDH and NSE levels. These factors allow for a comprehensive assessment of the disease burden and prognosis, guiding treatment decisions and monitoring treatment response.